Clinical Trial Update: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial (NCT06230224) compares odronextamab to standard of care in adults with previously treated aggressive B-cell non-Hodgkin lymphoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Odronextamab (odronextamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Status: RECRUITING